(AKCA) – Analyst Comments
-
UPDATE: BMO Capital Downgrades Akcea Therapeutics, Inc. (AKCA) to Market Perform
-
Akcea Therapeutics (AKCA) PT Trimmed to $39 at BMO Capital; Pfizer Deal Provides 'Immediate Value'
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to AKCA Stock Lookup